The effect of Alhagi Pseudalhagi distillate on ureteral stone expulsion

Protocol summary

Summary
This single blind randomized clinical trial is conducted on 100 renal colic patients with ureteral stones less than 6 mm, from 23/09/2009 to 20/03/2010. After obtaining written consent all patients receive Hydrochlorothiazide (25 mg/day), Tamsulosin (0.4 mg/day), and analgesics and through simple randomization half of them also receive 150 ml/day Alhagi Pseudalhagi distillate from "Padina Natural Products, Mashhad" in 3 divided doses in addition to aforementioned drugs. All patients are visited again 2 weeks later and those with non-descent of stone, progressive hydronephrosis, or severe and unbearable symptoms are treated as medical treatment failures. Otherwise, the patients are followed for another 2 weeks and if at the end of the four-week period no stone is passed they will be categorized as no-stone-pass at the end of treatment. The stone expulsion rate and the time required for that will be compared between two groups.

General information

Acronym
IRCT registration information
IRCT registration number: IRCT138804172134N1
Registration date: 2009-12-29, 1388/10/08
Registration timing: registered_while_recruiting

Last update: Update count: 0
Registration date
2009-12-29, 1388/10/08

Registrant information
Name
Ali Cyrus
Name of organization / entity
Arak University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 86 1888 1041
Email address
cyrus@arakmu.ac.ir

Recruitment status
Recruitment complete

Funding source
Arak University of Medical Sciences, Deputy of Research

Expected recruitment start date
2009-09-23, 1388/07/01
Expected recruitment end date
2010-03-20, 1388/12/29
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
The effect of Alhagi Pseudalhagi distillate on ureteral stone expulsion

Public title
The effect of Alhagi Pseudalhagi distillate on ureteral stone expulsion

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria: having ureteral stones ≤ 6 mm, not severe hydronephrosis, age more than 20 yr and less than 60 yr, no signs of UTI or fever according to physical findings and urine analysis, no known renal diseases according to history and preliminary laboratory exams, no mandatory restriction of fluids due to an underlying disease, no bilateral ureteral stones, not having a single kidney, no known allergic reaction to Alhagi Pseudalhagi distillate or gum, not being pregnant, and body weight between 50 to 100 kg. Exclusion criteria: patients' reluctance to continue participating in the study, no follow up visits, progressive hydronephrosis during follow up, occurrence of fever or UTI during follow up, repeated bouts of unbearable ureteral colics during follow up, allergic reactions or complications due to the treatment.

Age
From 20 years old to 60 years old

Gender
Both

Phase
1-2

Groups that have been masked
No information
Sample size
Target sample size: 100

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Single blinded

Blinding description

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1
Ethics committee
Name of ethics committee
Ethic committee of Arak University of Medical Sciences
Street address
Pardis Complex, Basij Square, Enghelab Square, Taleghani Ave.
City
Arak
Postal code
2008-10-29, 1387/08/08
Approval date
Ethics committee reference number
87-42-5

Health conditions studied

1
Description of health condition studied
Ureteral stone
ICD-10 code
N20.1
ICD-10 code description
Calculus of ureter

Primary outcomes

1
Description
Ureteral stone passage
Timepoint
2 and 4 weeks after commencement of therapy
Method of measurement
According to patients' report

Secondary outcomes

1
Description
Time to stone passage
Timepoint
2 and 4 weeks after commencement of therapy
Method of measurement
by asking the patients

Intervention groups

1
Description
The control group receive Hydrochlorothiazide (25 mg/day), Tamsulosin (0.4 mg/day), Diclofenac sodium suppository (100 mg PRN), and Tramadol inj. (50 mg IM PRN).
Category
Treatment - Drugs

2
Description
The intervention group receive Hydrochlorothiazide tablets (25 mg/day), Tamsulosin capsules (0.4 mg/day), Diclofenac sodium suppository (100 mg PRN), Tramadol inj. (50 mg IM PRN), and 150 ml/day Alhagi Pseudalhagi distillate from "Padina Natural Products, Mashhad" in 3 divided doses.
Category
Treatment - Drugs

Recruitment centers

1
Recruitment center
Name of recruitment center
Arak Vali Asr Hospital
Full name of responsible person
Dr. Ali Cyrus
Street address
Department of Surgery, Vali-Asr Hospital, Vali-Asr Square
City
Arak

Sponsors / Funding sources

1
Sponsor
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Dr. Saeed Changizie Ashtiani
Street address
Pardis Complex, Basij Square, Enghelab Square,
Taleghani Ave.
City
Arak

Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Arak University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries
Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Dr. Ali Cyrus
Position
Urologist/Associate professor
Other areas of specialty/work
Street address
Department of Surgery, Vali-Asr Hospital, Vali-Asr Square
City
Arak
Postal code
Phone
+98 86 1222 1041
Fax
+98 86 1222 0224
Email
cyrus@arakmu.ac.ir
Web page address

Person responsible for scientific inquiries
Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Dr. Ali Cyrus
Position
Urologist / Associate professor
Other areas of specialty/work
Street address
Department of Surgery, Vali-Asr Hospital, Vali-Asr Square
City
Arak
Postal code
Phone
+98 86 1222 1041
Fax
+98 86 1222 0224
Email
cyrus@arakmu.ac.ir
Web page address

Person responsible for updating data
Contact
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Dr. Ali Cyrus
Position
Urologist / Associate professor
Other areas of specialty/work
Street address
Department of Surgery, Vali-Asr Hospital, Vali-Asr Square
City
Arak
Postal code
Phone
+98 86 1222 1041
Fax
Email
Web page address

Sharing plan
Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty